Buenavista Equity Partners and Columbus Venture Partners agree to sell Syngoi Technologies to Artis BioSolutions

by Buenavista Equity Partners

Syngoi is a Contract Development and Manufacturing Organisation (CDMO) specialising in synthetic DNA for advanced therapies, a critical component for therapeutic applications such as mRNA vaccines, ge...

Read more

Columbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S. based Artis BioSolutions

by Columbus Venture Partners

Syngoi Technologies has developed in recent years its own enzymatic synthetic DNA platform, designed to address one of the key structural challenges in the gene and cell therapy industry: the efficien...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Laborai raises €3.7 million in a fundi...

by Laborai

Since its public launch in 2025, the platform has served more than 200...

Photos Stream